dc.contributor.author |
Nielsen, BN |
en |
dc.contributor.author |
Friis, SM |
en |
dc.contributor.author |
Rømsing, J |
en |
dc.contributor.author |
Schmiegelow, K |
en |
dc.contributor.author |
Anderson, Brian |
en |
dc.contributor.author |
Ferreirõs, N |
en |
dc.contributor.author |
Labocha, S |
en |
dc.contributor.author |
Henneberg, SW |
en |
dc.date.accessioned |
2017-08-08T00:41:51Z |
en |
dc.date.issued |
2014-02 |
en |
dc.identifier.citation |
Paediatric Anaesthesia 24(2):170-180 Feb 2014 |
en |
dc.identifier.issn |
1155-5645 |
en |
dc.identifier.uri |
http://hdl.handle.net/2292/34886 |
en |
dc.description.abstract |
Summary Background The management of procedural pain in children ranges from physical restraint to pharmacological interventions. Pediatric formulations that permit accurate dosing, are accepted by children and a have a rapid onset of analgesia are lacking. Objectives To investigate a pediatric formulation of intranasal sufentanil 0.5 mcg·kg -1 and ketamine 0.5 mg·kg -1 for procedural pain and to characterize the pharmacokinetic (PK) profile. Methods Fifty children (≥10 kg) scheduled for a painful procedure were included in this prospective nonrandomized open-label clinical trial. Thirteen of these children had central venous access for drug assay sampling; enabling a compartmental PK analysis using nonlinear mixed-effects models. Pain intensity before and during the procedure was measured using age-appropriate pain scales. Heart rate, oxygen saturation and sedation were recorded. Results Children had a mean age of 8.8 (sd 4.9) years and weight 35.2 (sd 20.1) kg. Sufentanil/ketamine nasal spray was effective (procedural pain intensity scores ≤5 (0-10)) in 78% of the painful procedures. The spray was well accepted by 94% of the children. Oxygen saturation and heart rate remained stable, and sedation was minimal. The bioavailability of sufentanil and ketamine was 24.6% and 35.8%, respectively. Maximum plasma concentration (C max ) of sufentanil was 0.042 mcg·l -1 (coefficient of variation (CV) 12.9%) at 13.8 min (CV 12.4%) (T max ). C max for ketamine was 0.102 mg·l -1 (CV 10.8%), and T max was 8.5 min (CV 17.3%). Conclusion Sufentanil/ketamine nasal spray provided rapid onset of analgesia for a variety of painful procedures with few adverse effects and has promising features for use in pediatric procedural pain management. © 2013 John Wiley & Sons Ltd. |
en |
dc.publisher |
Blackwell Publishing Inc. |
en |
dc.relation.ispartofseries |
Paediatric Anaesthesia |
en |
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
en |
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
en |
dc.title |
Intranasal sufentanil/ketamine analgesia in children |
en |
dc.type |
Journal Article |
en |
dc.identifier.doi |
10.1111/pan.12268 |
en |
pubs.issue |
2 |
en |
pubs.begin-page |
170 |
en |
pubs.volume |
24 |
en |
dc.rights.holder |
Copyright: Blackwell Publishing Inc. |
en |
dc.identifier.pmid |
24118506 |
en |
pubs.end-page |
180 |
en |
pubs.publication-status |
Published |
en |
dc.rights.accessrights |
http://purl.org/eprint/accessRights/RestrictedAccess |
en |
pubs.subtype |
Article |
en |
pubs.elements-id |
425370 |
en |
pubs.org-id |
Medical and Health Sciences |
en |
pubs.org-id |
School of Medicine |
en |
pubs.org-id |
Anaesthesiology |
en |
dc.identifier.eissn |
1460-9592 |
en |
pubs.record-created-at-source-date |
2017-08-08 |
en |
pubs.dimensions-id |
24118506 |
en |